An apolipoprotein B100 mimotope prevents obesity in mice
- Authors
- Kim, Hyo Joon; Lee, Hee Jong; Choi, Jung Soon; Han, Jemin; Kim, Ji Young; Na, Hyun Kyun; Joung, Hae-Jung; Kim, Young Sik; Binas, Bert
- Issue Date
- 1-1월-2016
- Publisher
- PORTLAND PRESS LTD
- Keywords
- ApoB100; high-fat-diet-induced obesity; humoral immunity; mimotope
- Citation
- CLINICAL SCIENCE, v.130, no.2, pp.105 - 116
- Indexed
- SCIE
SCOPUS
- Journal Title
- CLINICAL SCIENCE
- Volume
- 130
- Number
- 2
- Start Page
- 105
- End Page
- 116
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/89867
- DOI
- 10.1042/CS20150423
- ISSN
- 0143-5221
- Abstract
- Although apolipoprotein B100 (ApoB100) plays a key role in peripheral fat deposition, it is not considered a suitable therapeutic target in obesity. In the present study we describe a novel ApoB100 mimotope, peptide pB1, and the use of pB1-based vaccine-like formulations (BVFs) against high-fat diet (HFD)-induced obesity. In HFD-compared with chow-fed adolescent mice, BVFs reduced the 3-month body-weight gains attributable to increased dietary fat by 44-65 %, and prevented mesenteric fat accumulation and liver steatosis. The body-weight reductions paralleled the titres of pB1-reactive immunoglobulin G (IgG) antibodies, and pB1-reactive antibodies specifically recognized native ApoB100 and a synthetic peptide from the C-terminal half of ApoB100. In cultured 3T3L1 adipocytes, anti-pB1 antibodies increased lipolysis and inhibited low-density lipoprotein (LDL) uptake. In cultured RAW 264.7 macrophages, the same antibodies enhanced LDL uptake (without causing foam cell formation). These findings make ApoB100 a promising target for an immunization strategy against HFD-induced obesity.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.